Author

C. Baronti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Organism:virus· 2 Organism:mouse· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

F. Touret· 6 shared X. de Lamballerie· 6 shared A. Nougairede· 3 shared L. Luciani· 2 shared L. Thirion· 2 shared M. Cochin· 2 shared M. Gilles· 2 shared A. Dogliani· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

F. Touret

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals

S. Thebault, N. Lejal, A. Dogliani, A. Donchet, A. Urvoas, M. Valerio-Lepiniec, M. Lavie, C. Baronti, F. Touret, B. da Costa, C. Bourgon, A. Fraysse, A. Saint-Albin-Deliot, J. Morel, B. Klonjkowski, , B. Delmas

This paper identifies biosynthetic proteins (Reps) that bind the SARS-CoV-2 spike RBD and neutralize the virus, including variants, with high potency and stability.

bioRxiv · May 10, 2022Microbiology

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

F. Touret, C. Baronti, H. S. Bouzidi, X. de Lamballerie

The paper evaluates the neutralizing activity of eight therapeutic antibodies against an Omicron SARS-CoV-2 isolate and finds significant loss of efficacy for most, with only Sotrovimab showing minimal reduction.

bioRxiv · Jan 1, 2022Microbiology

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant

A. Weiss, F. Touret, C. Baronti, M. Gilles, B. Hoen, A. Nougairede, X. de Lamballerie, M. O. A. Sommer

This study shows niclosamide is effective against SARS-CoV-2 and its variants in a human airway model, supporting its potential as a COVID-19 therapy.

bioRxiv · Apr 26, 2021Microbiology

Alpha variant versus D614G strain in the Syrian hamster model

M. Cochin, L. Luciani, F. Touret, J. S. Driouich, P.-R. Petit, G. Moureau, C. Baronti, C. Laprie, L. Thirion, P. Maes, R. Boudewijns, J. Neyts, X. de Lamballerie, A. Nougairede

This study compares the SARS-CoV-2 Alpha variant and G614 strain in Syrian hamsters, finding similar replication and disease outcomes but a slight fitness advantage for G614.

bioRxiv · Apr 19, 2021 · PreprintMicrobiology

Replicative fitness SARS-CoV-2 20I/501Y.V1 variant in a human reconstituted bronchial epithelium

F. Touret, L. Luciani, C. Baronti, M. Cochin, J.-S. Driouich, M. Gilles, L. Thirion, A. Nougairede, X. de Lamballerie

This study compares the replication efficiency of the SARS-CoV-2 20I/501Y.V1 variant with an ancestral strain in human bronchial epithelium models, finding the variant outcompetes the ancestral strain in competition experiments.

bioRxiv · Mar 22, 2021Microbiology

Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery

F. Touret, C. Baronti, O. Goethals, M. Van Loock, X. De Lamballerie, G. Querat

This paper establishes a dengue virus panel representing all genotypes to aid in antiviral drug discovery, showing varying compound efficacies across genotypes.

bioRxiv · Feb 28, 2019Microbiology